The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

慢性阻塞性肺病（COPD）分为稳定期与急性加重期，慢阻肺急性加重期（AECOPD）的特征是患者呼吸系统症状急性恶化，超出了日常的变异，且需要改变药物治疗方案。AECOPD ...

Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

MP Cariappa, Public Health Specialist, Advisor, Tata Trusts shares inputs on understanding chronic lung diseases. He is also ...

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Regeneron REGN0.26%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.65%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of their ...